Trials / Not Yet Recruiting
Not Yet RecruitingNCT06440824
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romiplostim N01 | 2.0 µg/kg, subcutaneous injection, once a week, up to a maximum of 8 weeks. Stop medication when platelet count increases by 50 × 109/L or more compared to before medication |
| DRUG | Recombinant Human Thrombopoietin | 30000 U/d, subcutaneously injected once a day, for a maximum of 8 weeks. Medication should be stopped when platelets increase by 50 × 109/L or more compared to before medication |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2025-06-01
- Completion
- 2025-11-30
- First posted
- 2024-06-04
- Last updated
- 2024-06-04
Source: ClinicalTrials.gov record NCT06440824. Inclusion in this directory is not an endorsement.